Group Questions FDA on Other Avandia Risk

WASHINGTON (Reuters) - U.S. health authorities were aware of a type of heart risk linked to GlaxoSmithKline Plc's widely prescribed diabetes drug Avandia and another competitor nearly five years ago, consumer advocacy group Public Citizen said on Tuesday. In 2002, U.S. Food and Drug Administration staff scientists called for reports of congestive heart failure to be included on the label of Avandia as well as Actos, made by Takeda Pharmaceutical Co. Ltd., the group said, citing an internal FDA document.